PSNL

Personalis Inc

Add to Watchlist

Advanced Chart

5.590

+0.01(0.179%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.880

Open

5.6577

VWAP

Vol

986.95K

Mkt Cap

494.18M

Low

5.505

Amount

EV/EBITDA(TTM)

Total Shares

51.94M

310.81M

EV/OCF(TTM)

P/S(TTM)

4.46

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

23.83M

+41.83%

-0.259

+12.42%

18.87M

-26.58%

-0.264

-58.7%

20.12M

-10.91%

-0.244

+1.79%

Estimates Revision

The market is revising Upward the revenue expectations for Personalis, Inc. (PSNL) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by 47.88%.

Revenue Estimates for FY2025

Revise Upward

+0.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.01%

In Past 3 Month

Stock Price

Go Up

+47.88%

In Past 3 Month

8 Analyst Rating

27.73% Upside

Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 7.14 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

27.73% Upside

Current: 5.590

Low

5.00

Averages

7.14

High

9.00

27.73% Upside

Current: 5.590

Low

5.00

Averages

7.14

High

9.00

BTIG

NULL

Buy

maintain

$7 -> $8

2025-07-29

New

Reason

BTIG

Price Target

$7 -> $8

2025-07-29

New

maintain

NULL

Buy

Reason

BTIG raised the firm's price target on Personalis to $8 from $7 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.

Guggenheim

NULL -> Buy

initiated

2025-05-15

Reason

Guggenheim

Price Target

2025-05-15

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of Personalis with a Buy rating and $6 price target.

Guggenheim

analyst

initiated

2025-05-15

Reason

Guggenheim

analyst

Price Target

2025-05-15

initiated

Reason

As previously reported, Guggenheim initiated coverage of Personalis with a Buy rating and $6 price target. Personalis has built a best-in-class infrastructure to do comprehensive genomic, proteomic, and immune profiling in tissue and blood for therapy selection and MRD, says the analyst. While "the dreams of becoming a Porsche have faded far into the rearview mirror," management has reduced risk and is innovative in responsible revenue generation, adds the analyst, who views the company's products as "having a place on the market."

Needham

Mike Matson

Strong Buy

Reiterates

2025-04-10

Reason

Needham

Mike Matson

Price Target

2025-04-10

Reiterates

Strong Buy

Reason

Craig-Hallum

John Wilkin

Strong Buy

Initiates

2025-03-17

Reason

Craig-Hallum

John Wilkin

Price Target

2025-03-17

Initiates

Strong Buy

Reason

Craig-Hallum initiated coverage of Personalis with a Buy rating and $8 price target.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-02-28

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-02-28

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Personalis Inc (PSNL.O) is -6.05, compared to its 5-year average forward P/E of -6.11. For a more detailed relative valuation and DCF analysis to assess Personalis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.11

Current PE

-6.05

Overvalued PE

0.94

Undervalued PE

-13.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.91

Current EV/EBITDA

-5.32

Overvalued EV/EBITDA

2.49

Undervalued EV/EBITDA

-12.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.74

Current PS

6.73

Overvalued PS

10.90

Undervalued PS

0.57